Clinical Assessment of Malondialdehyde-Modified LDL for Atherosclerotic Disorders

1)胰岛素治疗可防止糖尿病患者LDL加速氧化，我们在一个研究人群中比较了丙二醛修饰的LDL（MDA-LDL）水平与血清脂质参数的浓度，发现MDA-LDL与载脂蛋白B（apo B）浓度之间有很强的相关性。它们之间的相互关系在载脂蛋白B浓度为1，150 mg/l时出现转折点。在糖尿病患者中，当apo B浓度高于1，150 mg/l时，MDA-LDL/apo B比值升高。该比值代表MDA对apo B的修饰程度。在对照组中，这一比例保持稳定。当我们将患者分为药物组（他汀类药物和胰岛素）时，我们发现1,150 mg/l的阈值消失了。当apo B浓度高于1,150 mg/l时，他汀组中MDA-LDL/apo B的比值与非药物组中的比值一样高。在胰岛素组中，所有载脂蛋白B水平范围内的MDA-LDL/载脂蛋白B平均值均降低至具有统计学意义的程度， 关于我们 与对照组的差异不大。总之，即使在载脂蛋白B浓度>1,150 mg/l时，胰岛素治疗仍能抑制LDL氧化，应注意其抗氧化特性。2）贝特类药物治疗对丙二醛修饰的LDL浓度的影响药物治疗被认为是临床预防糖尿病（DM）患者动脉粥样硬化病变的必要手段。为了证实贝特类药物治疗的效果，我们用梯度凝胶电泳法测定低密度脂蛋白（LDL）的大小，用酶联免疫法（ELISA）测定丙二醛修饰的LDL（MDA-LDL）的浓度，并阐明贝特类药物治疗期间载脂蛋白B（apo B）和MDA-LDL之间的关系。健康男性的平均MDA-LDL浓度高于健康女性。男性或女性的平均MDA-LDL浓度在年龄组之间没有显著差异。根据贝特类药物处理后apo B和MDA-LDL浓度的回归方程（y= 0.063 x +10.9），可能需要将apo B浓度降至1260 mg/l，以使MDA-LDL浓度恢复至对照浓度（65 +/-25单位/l）。apoB/MDA-LDL回归线的斜率约为nd药物治疗的斜率的一半（y=0.109x-10.8）。总之，贝特类药物治疗具有降低糖尿病患者血清MDA-LDL浓度的作用。少

1)Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes.In a study population, we compared the level of malondialdehyde-modified LDL (MDA-LDL) with the concentrations of lipid parameteis in serum and found a strong correlation between MDA-LDL and apolipoprotein B (apo B) concentrations. Their interrelations had a turning point at an apo B concentration of 1,150 mg/l. In diabetic patients, the ratio of MDA-LDL/apo B increased at apo B concentrations above 1,150 mg/l. This ratio represents the extent of modification of apo B by MDA. In the control subjects, this ratio remained stable. When we divided the patients into medication groups (statins and insulin), we found that the 1,150 mg/l threshold disappeared. At apo B concentrations above 1,150 mg/l, the ratio of MDA-LDL/apo B in the stalin group was as high as that in the non-drug group. In the insulin group, the means of MDA-LDL/apo B in all ranges of apo B levels decreased to an extent statistically indis … More tinguishable from those of the control group. In conclusion, insulin therapy represses LDL oxidation even at apo B concentrations>1,150 mg/l and should be noted for its anti-oxidation properties.2)Influence of fibrate treatment on malondialdehyde-modified LDL concentration.Drug therapy is considered essential to the clinical prevention of atherosclerotic lesions in patients with diabetes mellitus (DM). To confirm the effects of fibrate therapy, we determined low-density lipoprotein (LDL) size by gradient gel electrophoresis and malondialdehyde-modified LDL (MDA-LDL) concentrations by enzyme-linked immunosolvent assay (ELISA) and clarified the association between apolipoprotein B (apo B) and MDA-LDL during the fibrate therapy. Mean MDA-LDL concentrations were higher in healthy men than in healthy women. There were no significant differences in mean MDA-LDL concentrations between age groups for males or females. According to the regression equation (y=0.063x+10.9) obtained for apo B and MDA-LDL concentrations with fibrate treatment, the apo B concentration in those may need to be decreased to 1260 mg/l to restore the MDA-LDL concentration to the control concentration (65 +/-25 units/l). This slope of the apoB/MDA-LDL regression line was approximately half of that with nd-drug treatment (y=0.109x-10.8). In conclusion, fibrate therapy had an effect on reducing serum MDA-LDL concentration in diabetic patients. Less